You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PCNSL

Showing 26 - 50 of 120
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary CNS Lymphoma (PCNSL) Trial (Rituximab)

Not yet recruiting
  • Primary Central Nervous System Lymphoma (PCNSL)
  • (no location specified)
Dec 24, 2020

Lymphoma Trial in Worldwide (Nivolumab)

Completed
Has Results
  • Lymphoma
  • Birmingham, Alabama
  • +49 more
Nov 24, 2021

PCNSL Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Recruiting
  • PCNSL
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 16, 2020

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Lymphoma, Relapse Trial in France (Lenalidomide, Rituximab)

Completed
  • Lymphoma
  • Relapse
  • Clermont-Ferrand, Auvergne, France
  • +11 more
Dec 14, 2020

Primary CNS Lymphoma Trial (Penpulimab)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • (no location specified)
Apr 20, 2022

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

Not yet recruiting
  • Central Nervous System Lymphoma
  • Hefei, Anhui, China
  • +4 more
Jan 26, 2023

Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

Recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Phoenix, Arizona
  • +10 more
Feb 1, 2023

Primary CNS Lymphoma Trial in Beijing (Methotrexate, Rituximab, Lenalidomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, Dongcheng District, China
    Daobin Zhou
Jun 3, 2020

Primary CNS Non-Hodgkin Lymphoma Trial in Cleveland (rituximab, yttrium Y 90 ibritumomab tiuxetan)

Terminated
Has Results
  • Primary Central Nervous System Non-Hodgkin Lymphoma
  • rituximab
  • yttrium Y 90 ibritumomab tiuxetan
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jul 23, 2020

Primary Central Nervous Lymphoma, Intraocular Lymphoma Trial in France (Ibrutinib)

Completed
  • Primary Central Nervous Lymphoma
  • Intraocular Lymphoma
  • Clermont Ferrand, France
  • +9 more
Apr 6, 2022

Lymphoma, B-Cell Trial in Beijing, Shanghai, Chengdu (Keynatinib)

Recruiting
  • Lymphoma, B-Cell
  • Beijing, Beijing, China
  • +3 more
Apr 17, 2022

Primary CNS Lymphoma Trial in Paris (Rituximab, Methotrexate, Temozolomide)

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Rituximab, Methotrexate, Temozolomide
  • Paris, France
    Groupe Hospitalier Pitie Salpetriere
Feb 10, 2022

Primary CNS Lymphoma Trial in Milan (Lumbar puncture)

Recruiting
  • Primary CNS Lymphoma
  • Lumbar puncture
  • Milan, Italy/Lombardy, Italy
    IRCCS Ospedale San Raffaele
Sep 5, 2021

Primary CNS Lymphoma Trial in Hwasun (IBER salvage chemo followed by ibrutinib maintenance therapy)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • IBER salvage chemotherapy followed by ibrutinib maintenance therapy
  • Hwasun, Jeollanam-do, Korea, Republic of
    Chonnam National University Hwasun Hospital
Aug 22, 2019

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Molecular Diagnostic for VitreoRetinal Lymphoma

Not yet recruiting
  • Vitreoretinal Lymphoma
    • (no location specified)
    Apr 21, 2023

    Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • the dose-escalation phase
    • Zhengzhou, Henan, China
      Oncology Department of The First Affiliated Hospital of Zhengzho
    May 30, 2022

    Primary CNS Lymphoma Trial in Paris ([18F]-FDG PET/MR)

    Active, not recruiting
    • Primary Central Nervous System Lymphoma
    • [18F]-FDG PET/MR
    • Paris, France
      Pitié Salpêtrière Hospital
    Sep 9, 2021

    Primary CNS Lymphoma Trial in Worldwide (Rituximab, Methotrexate, Procarbazine)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Aarhus, Denmark
    • +34 more
    Nov 4, 2022

    Inpatient Hospice With Procurement of Brain Tumor Tissue on

    Terminated
    • Ependymomas
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Nov 30, 2019

      CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

      Recruiting
      • Central Nervous System Lymphoma
      • Secondary Central Nervous System Lymphoma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 23, 2023